 Item 2.
Consequently, no forward-looking statement can be guaranteed.
Overview.
The Company reflected income before income tax expense of $148,800 for the three months ended December 31, 2018 compared to $16,400 for the three months ended December 31, 2017, primarily due to an increase in earned royalties by the Bioprocessing Systems Operations and reduced losses by the Catalyst Research Instruments Operations.
The results reflected total non-cash amounts for depreciation and amortization of $76,000 and $151,900 for the three and six month periods ended December 31, 2018 compared to $77,000 and $154,100 for the corresponding three and six month periods in 2017.
The benchtop laboratory equipment sales reflected $458,700 of Torbal brand product sales for the three months ended December 31, 2018, compared to $359,900 in the three months ended December 31, 2017.
As of December 31, 2018, the order backlog for catalyst research instruments was $617,400, substantially all of which is expected to be shipped during fiscal year ending June 30, 2019, compared to $752,500 as of December 31, 2017.
The overall gross profit percentage for the three months ended December 31, 2018 increased to 45.1% compared to 40.5% for the three months ended December 31, 2017 due to higher sales and lower labor and overhead costs by the Catalyst Research Instruments Operations.
General and administrative expenses for the three months ended December 31, 2018 increased by $54,200 (13.3%) to $462,100 compared to $407,900 for the three months ended December 31, 2017, due to various small increases in expenses by the Benchtop Laboratory Equipment Operations and the Catalyst Research Instruments Operations..
Selling expenses for the three months ended December 31, 2018 increased $33,600 (15.7%) to $248,200 from $214,600 for the three months ended December 31, 2017, due to higher sales and marketing related expenses for the Benchtop Laboratory Equipment Operations.
Research and development expenses decreased by $23,500 (17.7%) to $109,400 for the three months ended December 31, 2018 compared to $132,900 for the three months ended December 31, 2017, primarily due to decreased new product development costs incurred by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division’s new automated pill counter anticipated to be launched in autumn 2019.
Total other income (expense), net was ($7,200) for the three months ended December 31, 2018 compared to $6,100 for the three months ended December 31, 2017 due to realized holding losses on investment securities.
As a result of the foregoing, the Company recorded net income of $118,400 for the three months ended December 31, 2018 compared to a net loss of ($81,000) for the three months ended December 31, 2017.
13



  The Six Months Ended December 31, 2018 Compared with The Six Months Ended December 31, 2017 



  Net revenues for the six months ended December 31, 2018 increased $1,028,500 (32.4%) to $4,201,800 from $3,173,300 for the six months ended December 31, 2018, reflecting an increase of $609,500 in net sales of benchtop laboratory equipment resulting from increased orders for Genie and Torbal brand products, an increase of $262,300 in net sales of catalyst research instruments derived from custom products, and an increase of $156,700 in bioprocessing royalties.
The benchtop laboratory equipment sales reflected $884,000 of Torbal brand product sales for the six months ended December 31, 2018, compared to $664,200 in the six months ended December 31, 2017.
The overall gross profit percentage for the six months ended December 31, 2018 was 45.7% compared to 38.4% for the six months ended December 31, 2017 as a result of the higher sales and fixed overhead of the Benchtop Laboratory Equipment Operations and improved gross margins by the Catalyst Research Instruments Operations.
General and administrative expenses for the six months ended December 31, 2018 increased $42,300 (5.1%) to $878,600 from $836,300 for the six months ended December 31, 2017 due to various increases in administrative expenses by the Benchtop Laboratory Equipment Operations and the Catalyst Research Instrument Operations.
Selling expenses for the six months ended December 31, 2018 increased $68,700 (16.5%) to $484,300 from $415,600 for the six months ended December 31, 2017, due to increased marketing efforts and sales commissions related to the Benchtop Laboratory Equipment Operations.
Research and development expenses decreased by $35,300 (13.5%) to $226,700 for the six months ended December 31, 2018 compared to $262,000 for the six months ended December 31, 2017, primarily due to decreased new product development activities by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division’s new automated pill counter anticipated to be launched in the autumn 2019.
Total other income (expense), net was $(5,400) for the three months ended December 31, 2018 compared to $6,400 for the three months ended December 31, 2017 principally due to realized losses on investment securities.
The Company reflected income tax expense of $65,900 for the six months ended December 31, 2018 compared to $23,500 for the six months ended December 31, 2017, primarily due to higher income.
As a result of the foregoing, the Company recorded net income of $260,500 for the six months ended December 31, 2018 compared to a net loss of ($313,600) for the six months ended December 31, 2017.
Liquidity and Capital Resources.
Cash and cash equivalents increased by $305,000 to $1,358,100 as of December 31, 2018 from $1,053,100 as of June 30, 2018 primarily due to income during the period.
Net cash provided by operating activities was $397,300 for the six months ended December 31, 2018 compared to $133,700 used during the six months ended December 31, 2017.
The current period reflected higher income and accounts receivable balances.
Net cash used in investing activities was $14,300 for the six months ended December 31, 2018 compared to $84,600 used during the six months ended December 31, 2017 principally due to lower capital equipment purchases during the current year period by the Benchtop Laboratory Equipment Operations.
The Company used $78,000 in financing activities in the six months ended December 31, 2018 compared to $106,100 in the six months ended December 31, 2017 mainly due to contingent consideration payments in the prior year.
The Company's working capital increased by $535,100 to $4,653,300 as of December 31, 2018 compared to $4,118,200, as of June 30, 2018 mainly due to the income during the period.
The Company has a Demand Line of Credit through December 2019 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently.
Advances on the line, are secured by a pledge of the Company’s assets including inventory, accounts, chattel paper, equipment and general intangibles of the Company.
As of December 31, 2018 no borrowings were outstanding under such line.
14 



  Item 4.
Controls and Procedures 



  Evaluation of Disclosure Controls and Procedures.
As of the end of the period covered by this report, based on an evaluation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), the Chief Executive and Chief Financial Officer of the Company has concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the SEC's rules and forms.
Changes in Internal Control Over Financial Reporting.
PART II – OTHER INFORMATION 



  Item 6.
Exhibits and Reports on Form 8-K 



 [DATA_TABLE_REMOVED]  



 Reports on Form 8-K: 



  Report dated January 25, 2019 reporting under items 1.01, 5.02, 5.07, and 9.01 



 15 



  SIGNATURE 



 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
[DATA_TABLE_REMOVED]  



 16
